Skip to main content

Table 1 Correlation of EGFR and pEGFR expression with clinicopathological parameters, ER/PR, c-erbB-2, pAkt, uPAR, MMP-14 and VEGFR-1/Flt-1

From: Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

Parameters Total EGFR PEGFR
    n (%) P n (%) P
Menopausal status Premenopausal 50 5 (10.0) NS 13 (26.0) NS
  Postmenopausal 104 13 (12.5)   42 (40.4)  
Histological type Ductal 121 15 (12.4) NS 41 (33.9) NS
  Lobular 32 3 (9.4)   13 (40.6)  
Histological grade 1 23 1 (4.3) NS 7 (30.4) NS
  2 90 11 (12.2)   35 (38.9)  
  3 36 6 (16.7)   11 (30.6)  
Nuclear grade 1 53 1 (1.9) 0.001 18 (34.0) NS
  2 53 5 (9.4)   23 (43.4)  
  3 47 12 (25.5)   13 (27.7)  
Tumour size <2 cm 37 2 (5.4) NS 13 (35.1) NS
  2 to 5 cm 91 11 (12.1)   32 (35.2)  
  >5 cm 25 5 (20.0)   9 (36.0)  
Lymph node status Noninfiltrated 61 6 (9.8) NS 19 (31.1) NS
  Infiltrated 91 12 (13.2)   35 (38.5)  
Stage 1 28 2 (7.1) NS 9 (32.1) NS
  2 97 12 (12.4)   33 (34.0)  
  3 27 4 (14.8)   12 (44.4)  
ER Negative 70 14 (20.0) 0.005 20 (28.6) NS
  Positive 83 4 (4.8)   35 (42.2)  
PR Negative 78 13 (16.7) NS 30 (38.5) NS
  Positive 75 5 (6.7)   25 (33.3)  
c-erbB-2 Negative(<10) 60 5 (8.3) NS 21 (35.0) NS
  Positive(≥ 10) 93 13 (14.0)   34 (36.6)  
pAkt Negative (<10) 49 3 (6.1) NS 12 (24.5) 0.008
  Positive (≥ 10) 72 11 (15.3)   35 (48.6)  
uPAR Negative (<15) 49 9 (18.3) NS 12 (24.5) 0.049
  Positive (≥ 15) 67 6 (9.0)   29 (43.3)  
MMP-14 Negative (= 0) 93 13 (14.0) NS 28 (30.1) 0.025
  Positive (>0) 29 2 (6.9)   16 (55.2)  
VEFGR-1/Flt-1 Negative (<30) 40 5 (12.5) NS 9 (22.5) 0.016
  Positive (≥ 30) 72 9 (12.5)   33 (45.8)  
  1. EGFR, epidermal growth factor receptor; ER, oestrogen receptor; MMP, matrix metalloproteinase; NS, not significant; pAkt, phosphorylated Akt; pEGFR, phosphorylated epidermal growth factor receptor; PR, progesterone receptor; uPAR, urokinase plasminogen activator receptor; VEGFR, vascular endothelial growth factor receptor.